(Reuters) -Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed ...

Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

If you’re in a calorie deficit – either from dieting or while taking a weight loss drug – these exercises help direct your ...

Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a serious complication.

Weight loss drugs are popular—but often expensive. Luckily, there are a few ways to lower the costs, which we explore in this article.

The actor said he lost 40 pounds taking GLP-1 medication before a negative side effect necessitated a change to a different ...

During his appearance on the " Armchair Expert " podcast on Monday, the "Frozen" actor opened up about taking weight loss ...

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

Winfrey opened up about her decision to use a medication to help her lose weight in an interview with People. Her new TV ...

The newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...